ECYT is vastly underappreciated in the market place. It's platform has so many applications in areas with large populations that badly need a new approach to their medical ailments. Including over 50% of cancers which over express folate to inflammatory disease and even polycysticn renal disease which often leads to renal failure. At the conference today the CFO indicated this new area of personal medicine was so widely misunderstood that it represented its greatest impediment to the appreciation of the market for this company. Here a company has the greatest platforms that I am aware of for a new approach to medical therapeutics and routinely trades less then 100k shares and is valued less then 100 million when you consider the cash it has.
I am an MD and biotech investor and this is the best investment opportunity I have ever seen.